임선화 교수 연구실
erratum|
bronze
·인용수 3
·2021
Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’
Dennis J. Slamon, Patrick Neven, Stephen Chia, Guy Jérusalem, Michelino De Laurentiis, Sun-Wha Im, Katarína Petráková, Giulia Bianchi, M. Martín, A. Nusch, Gabe S. Sonke, Luis de la Cruz‐Merino, J.T. Beck, Yan Ji, C. Wang, Uday Deore, A. Chakravartty, Juan Pablo Zarate, T Taran, Peter A. Fasching
IF 65.4Annals of Oncology
키워드
FulvestrantMedicineOncologyInternal medicineCancerHormone receptorProgression-free survivalBreast cancerMetastatic breast cancerEstrogen receptor